Enquire

Enrich your medicines pipeline

The research partner that creates innovative solutions, builds dynamic relationships and enriches your medicines pipeline across a range of human diseases

Our Services

Graphic showing vision and mission icons

Our Vision and Mission

Our strong vision and mission statements underpin everything we do at Domainex. They guide our team with a common purpose that ensures we deliver outstanding drug discovery services to our clients.

Integrated drug discovery Services

We offer a truly integrated approach for a faster route to drug discovery. Our dedicated experts will work collaboratively with you to provide tailored scientific solutions.

Cogs Graphic

King’s Award for Enterprise: International Trade 2023 winner

Domainex has been awarded a King’s Award for Enterprise recognising the company’s outstanding growth in international trade. The award is testament to the innovation, customer focus and dedication of the whole team.

Offerings

Research Phases

Therapeutic Areas

Target Classes

Approaches & Techniques

Case Studies

MAP4K4: Kinase inhibitors for cardioprotection following heart attacks

Domainex designed novel, potent, highly selective, small-molecule inhibitors of MAP4K4, with potential cardioprotective drug properties. View more

Tankyrase: Inhibitors for the treatment of solid tumours

Domainex employed its LeadBuilder virtual screening technology to identify tankyrase inhibitors from which pre-clinical development candidates emerged. View more

Der p 1: Protease Inhibitors for the treatment of asthma

Domainex collaborated with St George’s University London & the University of Manchester on a programme of drug discovery which led to the successfully nomination of a candidate drug. View more

TBK1/IKKε: Kinase inhibitors for the treatment of interferonopathies

Domainex identified a drug candidate DMXD-011, a first-in-class small-molecule orally bioavailable inhibitor of TBK1/IKKε View more

FLIPP-FADD: PPI inhibitors for the treatment of solid tumours

Domainex and Queen's University Belfast have discovered the world’s first inhibitors of FLIP-FADD and produced viable leads for drug candidate selection View more

Ras: PPI inhibitors for the treatment of cancer

Domainex used its extensive experience of fragment- & structure-based drug design to develop a lead molecule with strong binding to RAS, an oncology target. View more

G9a: Lysine Methyltransferase Inhibitors for the Treatment of Cancer

Starting from a LeadBuilder screen we identified novel potent inhibitors of G9a, which have potential to be developed as treatments for a range of solid tumours. View more

G9a: A fragment-based drug design (FBDD) programme to identify lysine methyltransferase inhibitors for the treatment of cancer

Domainex identified several highly efficient fragment hits and after one round of elaboration a 10-fold increase in affinity was achieved. View more

News

Medicinal Chemistry in Review: Merck Report the Discovery of MK-1468 as a Potent, Brain Penetrant LRRK2 Inhibitor for the Treatment of Parkinson’s Disease

Synthesis in Review: Photoredox Enabled Synthesis of Sulfonamides and Derivatives

Bringing new life to Sawston Village College’s wellbeing garden

Events

Jan 9 Postgraduate Symposium XVII – Biological and Medicinal Chemistry Symposium for Postgraduates 2023

Mar 3 9th Fragment-based Drug Discovery Meeting

Tweets

Tweets by Domainex_UK

Start your next project with Domainex

Contact one of our experts today